{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:56:17Z","timestamp":1762102577451,"version":"3.40.5"},"reference-count":18,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triple\u2010class\u2010refractory multiple myeloma (MM) describes MM refractory to proteasome inhibitors, immunomodulatory agents, and anti\u2010CD38 monoclonal antibodies. In the Phase IIb STORM study (NCT02336815), oral selinexor plus low\u2010dose dexamethasone (Sel\u2010dex) demonstrated a 26.2% overall response rate in triple\u2010class\u2010refractory MM. Here, we compare overall survival (OS) of 122 patients with triple\u2010class\u2010refractory MM who received Sel\u2010dex in STORM Part 2 with that of 64 similar patients treated with other available therapies in a Flatiron Health Analytic Database (FHAD) cohort. OS from the date that the patients\u2019 MM became triple\u2010class\u2010refractory was longer in STORM versus FHAD, with an unadjusted hazard ratio (HR) of 0.43 (<jats:italic>P<\/jats:italic>\u00a0=\u00a0\u00a0.0002; adjusted HR 0.35 [<jats:italic>P\u00a0\u00a0<\/jats:italic>=\u00a0\u00a0.011]). In a subset analysis of highly resistant patients receiving further therapies after their MM first became at least triple\u2010class\u2010refractory (i.e., who received Sel\u2010dex in STORM,<jats:italic>n<\/jats:italic>\u00a0=\u00a064, and non\u2010Sel\u2010dex in FHAD,<jats:italic>n<\/jats:italic>\u00a0=\u00a036), the OS was significantly longer in STORM with an unadjusted HR of 0.52 (<jats:italic>P\u00a0=\u00a0<\/jats:italic>.0331; adjusted HR 0.33 [<jats:italic>P<\/jats:italic>\u00a0=\u00a0.041]). Within the limits of this analysis, the OS of patients with at least triple\u2010class\u2010refractory MM was significantly better with Sel\u2010dex versus available therapies, suggesting that Sel\u2010dex may be associated with a meaningful OS benefit in these patients.<\/jats:p>","DOI":"10.1002\/jha2.120","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T16:02:18Z","timestamp":1606320138000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Overall survival with oral selinexor plus low\u2010dose dexamethasone versus real\u2010world therapy in triple\u2010class\u2010refractory multiple myeloma"],"prefix":"10.1002","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center Department of Medical Oncology Dana\u2010Farber Cancer Institute Harvard Medical School Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-7480","authenticated-orcid":false,"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan T.","family":"Vogl","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens School of Medicine Athens Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"CHU de Nantes\u2010H\u00f4tel Dieu Nantes France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Mayo Clinic Rochester Minnesota"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee\u2010Jen","family":"Wei","sequence":"additional","affiliation":[{"name":"Harvard T.H. Chan School of Public Health Boston Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[{"name":"Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[{"name":"Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"Myeloma Division John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Reichmann","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc. Newton Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Li","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc. Newton Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Tang","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc. Newton Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean\u2010Richard","family":"Saint\u2010Martin","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc. Newton Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Joshi","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc. Newton Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc. Newton Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin","family":"Shah","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc. Newton Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc. Newton Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute of Emory University Atlanta Georgia USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.329"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0689-1"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyy108"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-665018"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0283-0"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13046"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0049"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081983"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03655-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858852"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","unstructured":"ChenC GasparettoC WhiteD KotbR LipeB SutherlandHet\u00a0al.Selinexor pomalidomide and dexamethasone (SPd) in patients with relapsed or refractory multiple myeloma (RRMM). Abstract PF587.24th European Hematology Association Congress Amsterdam The Netherlands;2019.","DOI":"10.1097\/01.HS9.0000560636.62389.3a"},{"key":"e_1_2_7_18_1","unstructured":"GasparettoC LentzschS SchillerG CallanderNS TuchmanS ChenC et\u00a0al.Safety and efficacy of combination of selinexor daratumumab and dexamethasone (SDD) in patients with multiple myeloma (MM) previously exposed to proteasome inhibitors and immunomodulatory drugs.Presented at 24th EHA Congress June 13\u201316 Amsterdam The Netherlands;2019a."},{"key":"e_1_2_7_19_1","doi-asserted-by":"crossref","unstructured":"GasparettoC LentzschS SchillerG CallanderN ChenC WhiteD et\u00a0al.A phase 1b\/2 study of selinexor carfilzomib and dexamethasone (SKd) in relapsed\/refractory multiple myeloma (RRMM). Abstract PS1414.24th European Hematology Association Congress Amsterdam The Netherlands;2019b.","DOI":"10.1097\/01.HS9.0000563932.34778.38"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.120","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.120","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T09:00:24Z","timestamp":1698397224000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1002\/jha2.120"],"URL":"https:\/\/doi.org\/10.1002\/jha2.120","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"type":"print","value":"2688-6146"},{"type":"electronic","value":"2688-6146"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"2020-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}